|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 672.15 USD | -0.67% |
|
+1.37% | -12.92% |
| 07-20 | Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $965 From $968, Maintains Buy Rating | MT |
| 07-16 | Merck gets US FDA nod for first-in-its-class oral cholesterol drug | RE |
Company Valuation: Regeneron Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 66,029 | 77,057 | 93,403 | 76,639 | 79,193 | 68,384 | - | - |
| Change | - | 16.7% | 21.21% | -17.95% | 3.33% | -13.65% | - | - |
| Enterprise Value (EV) 1 | 56,196 | 77,057 | 84,542 | 70,331 | 73,294 | 60,561 | 57,871 | 54,617 |
| Change | - | 37.12% | 9.71% | -16.81% | 4.21% | -17.37% | -4.44% | -5.62% |
| P/E | 8.77x | 18.9x | 25.3x | 18.6x | 18.6x | 17.6x | 14.2x | 12.3x |
| PBR | 3.56x | 3.41x | 3.64x | 2.62x | 2.58x | 2.01x | 1.75x | 1.54x |
| PEG | - | -0.4x | -2.8x | 1.8x | 2.27x | -2.16x | 0.6x | 0.8x |
| Capitalization / Revenue | 4.11x | 6.33x | 7.12x | 5.4x | 5.52x | 4.31x | 3.88x | 3.61x |
| EV / Revenue | 3.5x | 6.33x | 6.45x | 4.95x | 5.11x | 3.81x | 3.28x | 2.88x |
| EV / EBITDA | 5.71x | 12.7x | 15.2x | 12.3x | 13.5x | 9.84x | 8.51x | 7.17x |
| EV / EBIT | 6.28x | 13.5x | 16.5x | 13.5x | 15x | 11.4x | 8.9x | 7.35x |
| EV / FCF | 8.61x | 17.4x | 21.8x | 19.2x | 18x | 9.8x | 9.5x | 7.96x |
| FCF Yield | 11.6% | 5.74% | 4.58% | 5.21% | 5.57% | 10.2% | 10.5% | 12.6% |
| Dividend per Share 2 | - | - | - | - | 3.52 | 3.903 | 4.433 | 5.001 |
| Rate of return | - | - | - | - | 0.46% | 0.58% | 0.66% | 0.74% |
| EPS 2 | 71.97 | 38.22 | 34.77 | 38.34 | 41.48 | 38.09 | 47.47 | 54.87 |
| Distribution rate | - | - | - | - | 8.49% | 10.2% | 9.34% | 9.12% |
| Net sales 1 | 16,072 | 12,173 | 13,117 | 14,202 | 14,343 | 15,880 | 17,646 | 18,967 |
| EBITDA 1 | 9,835 | 6,060 | 5,547 | 5,695 | 5,428 | 6,156 | 6,803 | 7,614 |
| EBIT 1 | 8,947 | 5,719 | 5,126 | 5,212 | 4,884 | 5,323 | 6,500 | 7,435 |
| Net income 1 | 8,075 | 4,338 | 3,954 | 4,413 | 4,505 | 3,989 | 5,026 | 5,678 |
| Net Debt 1 | -9,833 | - | -8,862 | -6,308 | -5,899 | -7,823 | -10,513 | -13,767 |
| Reference price 2 | 631.52 | 721.49 | 878.29 | 712.33 | 771.87 | 672.15 | 672.15 | 672.15 |
| Nbr of stocks (in thousands) | 104,556 | 106,802 | 106,347 | 107,590 | 102,599 | 101,739 | - | - |
| Announcement Date | 2/4/22 | 2/3/23 | 2/2/24 | 2/4/25 | 1/30/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 17.76x | 3.85x | 10.09x | 0.58% | 68.38B | |
| 25.64x | 5.3x | 15.59x | 0.61% | 51.69B | |
| 34.55x | 11.7x | 22.35x | -.--% | 42.1B | |
| -46.16x | 3.26x | 9.62x | 3.31% | 41.11B | |
| 24.47x | 3.57x | 11.94x | -.--% | 29.52B | |
| -7.13x | 10.08x | -6.19x | -.--% | 23.6B | |
| 77.55x | - | - | -.--% | 23.1B | |
| 64.32x | 6.31x | 43.41x | -.--% | 20.54B | |
| 24.47x | 5.19x | 13.62x | -.--% | 16.53B | |
| -36.62x | 17.52x | -47.76x | -.--% | 15.83B | |
| Average | 17.89x | 7.42x | 8.07x | 0.45% | 33.24B | |
| Weighted average by Cap. | 16.81x | 6.47x | 10.99x | 0.62% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- REGN Stock
- Valuation Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
